|Last Price$49.32||Day Change (%)0.41%|
|Open Price$49.16||Day Change ($)0.20|
|Day Range49.00–49.49||52-Week Range41.11–57.49|
As of Wed 07/23/2014 03:31 PM EST | USD
Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma
Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement Services In Long-Term Program
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
U.S. Hot Stocks: Hot Stocks to Watch
Research and Markets: PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
There is more competition among dividend-growth funds, making it harder to truly stand out.
Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.